Barclays PLC Intercept Pharmaceuticals, Inc. Call Options Transaction History

Barclays PLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2020 May 13, 2020	BUY	$48.35 - $118.68 $222,410 - $545,928	4,600 Added 511.11%	5,500 $346,000
Q4 2019 Feb 10, 2020	BUY	$57.36 - $124.1 $5,736 - $12,410	100 Added 12.5%	900 $112,000
Q3 2019 Nov 14, 2019	SELL	$58.69 - $80.46 $5,869 - $8,045	-100 Reduced 11.11%	800 $53,000
Q2 2019 Aug 14, 2019	SELL	$77.77 - $120.68 $147,763 - $229,292	-1,900 Reduced 67.86%	900 $72,000
Q1 2019 May 15, 2019	SELL	$91.83 - $120.68 $18,366 - $24,136	-200 Reduced 6.67%	2,800 $313,000
Q4 2018 Feb 14, 2019	BUY	$85.79 - $126.46 $223,054 - $328,796	2,600 Added 650.0%	3,000 $302,000
Q3 2018 Nov 14, 2018	BUY	$88.49 - $127.55 $8,849 - $12,755	100 Added 33.33%	400 $51,000
Q2 2018 Aug 14, 2018	SELL	$60.0 - $85.67 $12,000 - $17,134	-200 Reduced 40.0%	300 $25,000
Q1 2018 May 15, 2018	SELL	$52.72 - $67.25 $4.31 Million - $5.49 Million	-81,700 Reduced 99.39%	500 $31,000
Q4 2017 Feb 14, 2018	BUY	$58.2 - $72.76 $3.45 Million - $4.31 Million	59,200 Added 257.39%	82,200 $4.8 Million
Q3 2017 Nov 14, 2017	BUY	$57.01 - $118.75 $1.31 Million - $2.73 Million	23,000	23,000 $1.34 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.